Upon anti-PD-1 treatment, tumors demonstrate hyperprogression, which can be attributed to the abundance of Treg cells within the tumor microenvironment; erdafitinib treatment can reverse this by targeting FGFR1 on the Treg cell surface [9]. The gene discussed is PDCD1; the disease is neoplasm.